Article Dans Une Revue Vaccine Année : 2008

Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination

Résumé

Chemokine receptors are promising targets for enhancing T-cell immunity and anti-cancer therapy. CCL5 is a potential adjuvant for DNA vaccination. We postulated that CCR5 superagonists could be even more effective. A CCR5 superagonist derived from natural CCL5 by directed in vitro evolution, namely 1P7, is used as a DNA vaccine adjuvant and expressed as fused chemokine-Ig (1P7-Ig). We show that OVA + 1P7-Ig DNA co-inoculation induced higher frequencies of OVA-specific CD8 lymphocytes than OVA + CCL5-Ig or controls and gave an even better protection against tumor growth in a CCR5-dependant manner. Our results indicate that CCR5-superagonists may provide potent adjuvants for vaccines.

Domaines

Fichier principal
Vignette du fichier
JVAC-S-07-00664 final.pdf (1.01 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence
Loading...

Dates et versions

hal-02480557 , version 1 (16-02-2020)

Licence

Identifiants

Citer

Karim Dorgham, Valérie Abadie, Mutsunori Iga, Oliver Hartley, Guy Gorochov, et al.. Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination. Vaccine, 2008, 26 (26), pp.3252-3260. ⟨10.1016/j.vaccine.2008.04.003⟩. ⟨hal-02480557⟩
73 Consultations
223 Téléchargements

Altmetric

Partager

  • More